Free Trial

Pro-Dex (PDEX) Competitors

Pro-Dex logo
$40.71 -1.63 (-3.85%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$40.78 +0.06 (+0.16%)
As of 08/14/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDEX vs. EMBC, AXGN, ZIMV, BVS, CBLL, AVNS, KIDS, SMLR, SI, and DCTH

Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include Embecta (EMBC), AxoGen (AXGN), ZimVie (ZIMV), Bioventus (BVS), CeriBell (CBLL), AVANOS MEDICAL (AVNS), OrthoPediatrics (KIDS), Semler Scientific (SMLR), Shoulder Innovations (SI), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.

Pro-Dex vs. Its Competitors

Pro-Dex (NASDAQ:PDEX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Pro-Dex has a net margin of 14.61% compared to Embecta's net margin of 7.58%. Pro-Dex's return on equity of 29.08% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Pro-Dex14.61% 29.08% 16.19%
Embecta 7.58%-23.40%14.46%

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 47.5% of Pro-Dex shares are held by company insiders. Comparatively, 0.4% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Embecta has higher revenue and earnings than Pro-Dex. Embecta is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$53.84M2.46$2.13M$2.8014.54
Embecta$1.12B0.72$78.30M$1.439.70

Pro-Dex has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Pro-Dex presently has a consensus target price of $56.00, suggesting a potential upside of 37.56%. Embecta has a consensus target price of $19.00, suggesting a potential upside of 36.99%. Given Pro-Dex's stronger consensus rating and higher probable upside, equities research analysts clearly believe Pro-Dex is more favorable than Embecta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Embecta
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Embecta had 15 more articles in the media than Pro-Dex. MarketBeat recorded 16 mentions for Embecta and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.88 beat Embecta's score of 0.55 indicating that Pro-Dex is being referred to more favorably in the media.

Company Overall Sentiment
Pro-Dex Very Positive
Embecta Positive

Summary

Pro-Dex beats Embecta on 10 of the 15 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PDEX vs. The Competition

MetricPro-DexMED/DENTAL IndustryMedical SectorNASDAQ Exchange
Market Cap$138.07M$15.04B$5.61B$9.84B
Dividend YieldN/A1.48%4.61%4.07%
P/E Ratio14.5417.8930.2825.74
Price / Sales2.462.43460.47115.79
Price / Cash44.2216.2838.2159.48
Price / Book4.513.708.856.15
Net Income$2.13M$430.42M$3.25B$265.06M
7 Day Performance-14.74%-0.17%3.72%2.60%
1 Month Performance-9.89%3.13%5.86%2.83%
1 Year Performance109.63%13.40%30.34%25.58%

Pro-Dex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDEX
Pro-Dex
3.2549 of 5 stars
$40.71
-3.8%
$56.00
+37.6%
+118.1%$138.07M$53.84M14.54140Positive News
EMBC
Embecta
4.7427 of 5 stars
$9.79
-1.7%
$19.00
+94.1%
-6.0%$582.09M$1.08B10.882,100Earnings Report
AXGN
AxoGen
2.9182 of 5 stars
$12.55
-0.9%
$24.50
+95.2%
+38.6%$577.04M$187.34M-83.66450Short Interest ↑
ZIMV
ZimVie
0.4513 of 5 stars
$18.77
+0.1%
$17.75
-5.4%
+13.6%$529.05M$449.75M-26.811,770Short Interest ↑
BVS
Bioventus
3.017 of 5 stars
$6.32
+2.3%
$13.75
+117.6%
-8.3%$519.15M$567.70M-10.361,200
CBLL
CeriBell
2.4813 of 5 stars
$15.23
+7.7%
$32.14
+111.0%
N/A$511.06M$65.44M0.00N/A
AVNS
AVANOS MEDICAL
1.7701 of 5 stars
$11.28
+2.7%
N/A-51.4%$507.76M$687.80M-1.352,227Short Interest ↑
KIDS
OrthoPediatrics
3.9917 of 5 stars
$20.53
+0.7%
$35.83
+74.5%
-24.5%$495.20M$204.73M-11.73200
SMLR
Semler Scientific
3.3206 of 5 stars
$35.37
+2.6%
$82.00
+131.8%
+25.1%$475.15M$56.29M-13.55120Gap Up
SI
Shoulder Innovations
N/A$14.35
+0.7%
N/AN/A$454.31M$34.57M-0.4861Positive News
DCTH
Delcath Systems
2.6732 of 5 stars
$11.27
+6.4%
$24.00
+113.0%
+42.3%$368.81M$37.21M-22.5460Short Interest ↑

Related Companies and Tools


This page (NASDAQ:PDEX) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners